Table 1 Comparisons of clinicopathological variables and semi-quantitative parameters on ¹⁸F-FDG PET/CT between c-Met positive and negative patients

 Male

41 (67.2%)

20 (60.6%)

21 (75.0%)

0.233^†

 Female

20 (32.8%)

13 (39.4%)

7 (25.0%)

Median age (range)

62 (36–81)

61 (36–74)

64 (38–81)

0.541^#

 WDA

17 (27.9%)

12 (36.4%)

5 (17.9%)

0.373†

 MDA

18 (29.5%)

9 (27.3%)

9 (32.1%)

 PDA

21 (34.4%)

9 (27.3%)

12 (42.9%)

 MAC/SRC

5 (8.2%)

3 (9.1%)

2 (7.1%)

 Intestinal

23 (46.9%)

13 (48.1%)

10 (45.5%)

0.851†

 Non-intestinal

26 (53.1%)

14 (51.9%)

12 (54.5%)

 Median (range)

2.9 (0.4–776.4)

2.9 (0.4–776.4)

3.1 (1.1–242.0)

0.399^#

 Median (range)

9.0 (0.6–597.4)

8.4 (0.6–597.4)

10.1 (0.6–69.2)

0.510^#

 Median (range)

2.8 (0.8–131.2)

3.2 (0.8–131.2)

2.0 (0.9–79.3)

0.288^#

 Locoregional

26 (42.6%)

11 (33.3%)

15 (53.6%)

0.111^†

 Distant metastasis

35 (57.4%)

22 (66.7%)

13 (46.4%)

SUV_max (mean ± SD)

8.8 ± 6.40

9.6 ± 7.40

8.0 ± 4.91

0.335^*

SUV_peak (mean ± SD)

7.2 ± 5.22

7.7 ± 5.99

6.6 ± 4.08

0.438^*

MTV (mL, mean ± SD)

57.4 ± 54.39

70.8 ± 53.11

41.1 ± 52.32

0.034^*

TLG (g, mean ± SD)

328.2 ± 417.44

428.4 ± 442.95

205.7 ± 354.40

0.039^*

PFS, Median (95%CI)

14.5 (2.0–82.2)

11.5 (7.8–15.2)

17.6 (15.1–20.1)

0.039^‡

OS, Median (95%CI)

20.0 (5–86.2)

17.0 (13.9–20.5)

24.3 (17.0–31.6)

0.043^‡